Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EML4 | Q9HC35 | 9/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.33 |
| ▸ | SYK | P43405 | 4/20 | 0.33 |
| ▸ | RET | P07949 | 8/20 | 0.32 |
| ▸ | ROS1 | P08922 | 8/20 | 0.32 |
| ▸ | FLT3 | P36888 | 8/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30206015 | 0.99 | EML4 (0.33) | EML4ALKSYKRETROS1 | |
| SCHEMBL24943828 | 0.90 | CDK2 (0.37) | SYKJAK2 | |
| SCHEMBL30205698 | 0.88 | BTK (0.34) | EML4ALKSYKRETROS1 | |
| SCHEMBL24944206 | 0.88 | BTK (0.34) | EML4ALKSYKRETROS1 | |
| SCHEMBL24944789 | 0.87 | EML4 (0.32) | EML4ALKSYKRETROS1 | |
| SCHEMBL24944970 | 0.87 | LCK (0.40) | EML4ALKSYKRETROS1 | |
| Formic Acid SCHEMBL30206333 | 0.87 | EGFR (0.39) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24944457 | 0.86 | EML4 (0.32) | EML4ALKSYKRETROS1 | |
| SCHEMBL24943848 | 0.86 | EML4 (0.33) | EML4ALKSYKRETROS1 | |
| SCHEMBL24944750 | 0.86 | EGFR (0.41) | EML4ALKSYKRETROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |